Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
Join SeekPeptides .
We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition
(PubMed) Olthof MR, Brink EJ, Katan MB, Verhoef P
If a meal works, repeat it